Tandem Diabetes Care (NSDQ:TNDM) last week launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S.
The company’s latest pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia.
Using the Basal-IQ algorithm, the system predicts where a user’s blood sugar levels are heading up to 30 minutes into the future. When the algorithm predicts low glucose levels, the device suspends insulin delivery and automatically resumes once glucose levels begin to rise, according to Tandem.
Tandem’s pump also includes the newest continuous glucose monitoring system from Dexcom (NSDQ:DXCM), eliminating the need for fingersticks to calibrate the CGM.
Customers that are using older versions of Tandem’s t:slim X2 pump have the option to add the Basal-IQ technology via a remote software update. Tandem said it expects to begin shipping its latest generation of pumps by the end of August.
“This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” president & CEO Kim Blickenstaff said in prepared remarks. “Our ability to provide remote software updates, allowing in-warranty t:slim X2 Pump users the ability to add Basal-IQ Technology to their current pumps using a personal computer, is unparalleled in the industry and further differentiates the t:slim X2 Insulin Pump from other devices on the market.”
Tandem won FDA approval for the t:slim X2 pump with Basal-IQ tech in June this year.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.